In mammals, maintenance of energy and nutrient homeostasis during food deprivation is accomplished through an increase in mitochondrial fatty acid oxidation in peripheral tissues. An important component that drives this cellular oxidative process is the transcriptional coactivator PGC-1a. Here, we show that fasting induced PGC-1a deacetylation in skeletal muscle and that SIRT1 deacetylation of PGC-1a is required for activation of mitochondrial fatty acid oxidation genes. Moreover, expression of the acetyltransferase, GCN5, or the SIRT1 inhibitor, nicotinamide, induces PGC-1a acetylation and decreases expression of PGC-1a target genes in myotubes. Consistent with a switch from glucose to fatty acid oxidation that occurs in nutrient deprivation states, SIRT1 is required for induction and maintenance of fatty acid oxidation in response to low glucose concentrations. Thus, we have identified SIRT1 as a functional regulator of PGC-1a that induces a metabolic gene transcription program of mitochondrial fatty acid oxidation. These results have implications for understanding selective nutrient adaptation and how it might impact lifespan or metabolic diseases such as obesity and diabetes.
Introduction
Mammals have adapted to different environmental conditions and food by coordinating changes in tissue-specific metabolic pathways to maintain energy and nutrient homeostasis. Among the changes in food availability, nutrient deprivation triggers a whole rearrangement of glucose and lipid metabolism in key metabolic tissues such as skeletal muscle and liver. As glucose is the main fuel substrate for neuronal and red blood cells, peripheral tissues undergo a major shift from glucose to fatty acid oxidation, and gluconeogenic precursors such as lactate and alanine are delivered from muscle to the liver to synthesize glucose (Storlien et al, 2004) . In muscle cells, a major regulatory metabolic enzyme that allows this nutrient shift is pyruvate dehydrogenase kinase-4 (PDK4) that inactivates pyruvate dehydrogenase (PDH) by phosphorylation and prevents the entry of pyruvate into the TCA cycle. PDK4 enzymatic activity is regulated by nutrient deprivation (Sugden et al, 1993) . At the transcriptional level, several transcription factors including FOXO1, ERRa and PPARa are activators of PDK4 gene expression (Pilegaard and Neufer, 2004) . Interestingly, PGC-1a, a common transcriptional coactivator of these factors, also induces PDK4, consistent with a key role of PGC-1a in fatty acid utilization (Wende et al, 2005) . Furthermore, as PGC-1a induces OXPHOS genes involved in the final step of electron transport chain and ATP synthesis, it allows complete mitochondrial oxidation of fatty acids (Wu et al, 1999; Koves et al, 2005) .
Nutrient or caloric restriction results in major tissuespecific metabolic changes that ultimately cause an increase of longevity in many different organisms (Bordone and Guarente, 2005; Sinclair, 2005) . A key component of this response is Sir2, an NAD þ -dependent protein deacetylase that mediates increases of lifespan in response to restriction of nutrients (Bordone and Guarente, 2005) . Genetic evidence for a role of Sir2 in this nutrient/aging pathway has been provided in model organisms such as yeast (Kaeberlein et al, 1999) , worms (Tissenbaum and Guarente, 2001 ) and flies (Rogina and Helfand, 2004) . Interestingly, in yeast, caloric restriction by lowering glucose levels has been associated with increased rates of respiration in an Sir2-dependent pathway to allow a more efficient use of fuel substrates (Lin et al, 2000) . In mammals, SIRT1 controls different tissue-specific metabolic processes. For example, the ability of SIRT1 to repress PPARg confers increases of lipolytic rates in white adipose tissue (Picard et al, 2004) and insulin secretion in b-pancreatic cells (Bordone et al, 2006) . Moreover, we have previously shown that SIRT1 is increased in fasted liver to deacetylate and activate PGC-1a to promote hepatic glucose output (Rodgers et al, 2005) . Together, these metabolic adaptations transcriptionally controlled by SIRT1 might be important for the effects of nutrient restriction in organismal survival and longevity. PGC-1a is a metabolic coactivator that by interacting with transcription factors induces mitochondrial biogenesis and respiration (Lin et al, 2005; Finck and Kelly, 2006) . In skeletal muscle cells, PGC-1a is sufficient to convert to type I fibers that are rich in mitochondria and highly oxidative (Lin et al, 2002) . In addition, interaction of PGC-1a with PPARa and ERRa transcription factors potently induces fatty acid oxidation genes such as MCAD and CPT-1b (Vega et al, 2000; Huss et al, 2002; Mootha et al, 2004; Schreiber et al, 2004) . Interestingly, PGC-1a and mitochondrial OXPHOS targets are downregulated in human skeletal muscle of type II diabetic patients that might be linked to increased intramyocellular triglyceride accumulation and insulin resistance (Mootha et al, 2003; Patti et al, 2003) . In fact, there is a strong correlation between the presence of intramyocellular lipid in skeletal muscle and liver and progression of type II diabetes (Guan et al, 2002; Kelley et al, 2002; Petersen et al, 2004) . Therefore, a knowledge of the molecular mechanisms by which cells increase the rates of fatty acid oxidation in response to low nutrients is important to understand the pathophysiology of these metabolic diseases and their connection to aging biology.
We report here the identification of SIRT1 as the main deacetylase of PGC-1a that positively regulates mitochondrial and fatty acid utilization genes. Moreover, SIRT1 is required for increased rates of fatty acid oxidation in response to low glucose, providing a new metabolic regulator that allows mammalian cells to switch from glucose to fatty acid oxidation in nutrient deprivation conditions.
Results

SIRT1 deacetylates PGC-1a in skeletal muscle cells
Skeletal muscle undergoes a major metabolic reprogramming under nutrient deprivation conditions (Shuldiner and McLenithan, 2004) . PGC-1a has been previously shown to regulate different metabolic pathways in muscle cells, leading to a more oxidative capacity towards lipid utilization (Lin et al, 2005) . In liver cells, PGC-1a acetylation decreases in fasting conditions mainly through activation of SIRT1 deacetylase (Rodgers et al, 2005) . In order to determine whether changes in PGC-1a acetylation also occurred in skeletal muscle, PGC-1a was immunoprecipitated from muscle tissue in fed and fasted conditions. Figure 1A shows that fasting strongly induced PGC-1a deacetylation. To investigate whether SIRT1 could target PGC-1a in cultured muscle cells, we treated C 2 C 12 with nicotinamide, an SIRT1 inhibitor. As shown in Figure 1B , nicotinamide induced PGC-1a acetylation and was blocked with ectopic expression of SIRT1. GCN5 acetyltransferase is part of a major protein complex associated with PGC-1a and acetylates PGC-1a (Lerin et al, 2006) . Consistent with these results, PGC-1a was also acetylated by GCN5 in muscle cells ( Figure 1B) . Interestingly, treatment with nicotinamide and GCN5 strongly synergized to acetylate PGC-1a and again expression of SIRT1 largely decreased PGC-1a acetylation. To demonstrate further that SIRT1 is the main PGC-1a deacetylase, we used SIRT1À/À mouse embryonic fibroblasts (MEFs) (Chua et al, 2005) . As shown in Figure 1C , in SIRT1 þ / þ MEFs, PGC-1a was deacetylated and treatment with nicotinamide induced its acetylation. In contrast, in SIRT1À/À MEFs, PGC-1a was constitutively acetylated and nicotinamide did not further increase it. Importantly, in these cells, deacetylation of PGC-1a was totally rescued by expression of SIRT1 ( Figure 1D ).
To demonstrate that SIRT1 localized to PGC-1a target genes in skeletal muscle cells, we performed ChIP assays ( Figure 1E ). SIRT1 was bound to promoters of PGC-1a targets such as cytochrome c, PDK4 and PGC-1a. Ectopic expression of PGC-1a induced a 7-10-fold recruitment of SIRT1 to these promoters. Together, these results indicate that PGC-1a is deacetylated by SIRT1 in skeletal muscle cells and SIRT1 localized to promoters that are controlled by PGC-1a, suggesting a regulatory role of SIRT1 on the expression of these genes.
SIRT1 regulates mitochondrial and fatty acid metabolism
In skeletal muscle cells, PGC-1a activates mitochondrial gene expression in response to energy demands (Wu et al, 1999; Lin et al, 2002) . As SIRT1 was localized to promoters controlled by PGC-1a, we investigated whether SIRT1 regulated PGC-1a-induced mitochondrial gene expression in myotubes infected with adenoviruses expressing PGC-1a and SIRT1 shRNA ( Figure 2G ). As expected, PGC-1a increased a repertoire of mitochondrial gene expression, including regulatory genes ERRa, genes of the TCA cycle (IDH3a), respiratory chain (cyt-c, COXVa) and fatty acid utilization (MCAD, CPT1b and PDK4). Remarkably, PGC-1a-increased mitochondrial and fatty acid utilization gene expression was largely prevented by knocking down SIRT1 (Figure 2A and B). Mitochondrial transcriptional regulator ERRa, but not NRF-1, followed exactly the same pattern ( Figure 2C ). However, the glycolytic gene pyruvate kinase did not change under these conditions ( Figure 2D ). These fluctuations in gene expression translated to an increase in fatty acid oxidation induced by PGC-1a that was prevented by SIRT1 knockdown ( Figure 2E ). Interestingly, in these conditions, shRNA SIRT1 prevented PGC-1a-decreased glucose oxidation ( Figure 2F ). These data indicate that SIRT1 is required, at least in part, for maximum expression of a large set of PGC-1a target genes and increased fatty acid oxidation.
The effects of knocking down SIRT1 on gene expression without ectopic PGC-1a expression were very minor in C 2 C 12 muscle cells ( Figure 2 ). As these cells express very low levels of PGC-1a, we used primary skeletal muscle cells that express a significant level of PGC-1a. We tested whether SIRT1 was required to maintain mitochondrial and fatty acid oxidation gene expression. Primary myotubes transduced with an adenovirus expressing SIRT1 shRNA resulted in an efficient knockdown of SIRT1 ( Figure 3E ). The expression levels of mitochondrial and fatty acid utilization genes ( Figure 3A and B) were significantly reduced in the cells transduced with SIRT1 shRNA. Interestingly, PGC-1a and its target mitochondrial transcriptional regulators, ERRa and mtTFA, were also downregulated ( Figure 3C ). These gene expression changes functionally translated to decreases in TCA cycle measured by citrate synthase activity ( Figure 3D ). These results indicate that SIRT1 controls a broad set of genes involved in mitochondrial oxidative function in muscle cells.
To have genetic evidence to further support the role of SIRT1 regulating mitochondrial and fatty acid oxidation functions, we analyzed the same set of genes in MEFs lacking SIRT1. SIRT1À/À MEFs displayed a decrease in expression of genes associated with mitochondrial ( Figure 4A ), fatty acid utilization ( Figure 4B ) and mitochondrial transcriptional regulators compared with wild-type cells ( Figure 4C ). To directly show that these effects were entirely dependent on SIRT1, we ectopically expressed SIRT1 in SIRT1À/À MEFs. Importantly, this decreased gene expression pattern was entirely rescued by SIRT1 in a dose-dependent manner ( Figure 4D ). Moreover, these changes in gene expression resulted in a decreased rate of fatty acid oxidation in SIRT1À/À cells ( Figure 4E ). Taken together, these results indicate that SIRT1 positively regulates complete mitochondrial and fatty acid oxidation, and at least in skeletal muscle cells, SIRT1 largely contributes to the effects of PGC-1a in regulating expression of genes linked to these metabolic pathways.
GCN5 and nicotinamide regulate mitochondrial and fatty acid metabolism in skeletal muscle cells
We have recently identified GCN5 as the main PGC-1a acetyltransferase and a negative regulator of PGC-1a biological functions (Lerin et al, 2006) . We therefore investigated whether GCN5, by opposing SIRT1-positive effects, would negatively regulate PGC-1a function on mitochondrial and fatty acid utilization genes. Indeed, in C 2 C 12 myotubes, GCN5 largely abolished PGC-1a-induced mitochondrial, fatty acid utilization and mitochondrial transcriptional regulator gene expression ( Figure 5A ). As C 2 C 12 muscle cells express low levels of endogenous PGC-1a, we again used primary skeletal myotubes to analyze the effects of GCN5 expression. The same pattern of gene expression was observed in these cells, but without ectopically expressing PGC-1a (Supplementary Figure S1 ). To support that these effects of GCN5 were mediated through acetylation of PGC-1a, we used the SIRT1 inhibitor, nicotinamide. Consistent with the effects of GCN5, treatment of C 2 C 12 or primary skeletal muscle cells with nicotinamide caused a decrease in expression of PGC-1a targeted mitochondrial and fatty acid utilization Fasting-induced PGC-1a deacetylation in skeletal muscle. Mice were either fed or fasted for 16 h and skeletal muscle was used to immunoprecipitate PGC-1a and Western blot was performed to detect PGC-1a levels and acetylation. (B) Nicotinamide and GCN5 induce PGC-1a acetylation. C 2 C 12 myotubes were treated with 5 mM nicotinamide for 12 h and/or infected with the indicated adenoviruses for 48 h. After treatment, cells were harvested and protein cell extracts were used for PGC-1a immunoprecipitation and Western blot analysis using the specified antibodies. (C) PGC-1a is constitutively acetylated in SIRT1À/À MEFs. MEFs were treated with nicotinamide and/or infected with adenoviruses encoding PGC-1a as described in (B). (D) SIRT1 rescues PGC-1a deacetylation in SIRT1À/À MEFs. Adenoviruses expressing PGC-1a and SIRT1 were infected in MEFs as described in (B). (E) SIRT1 is bound to PGC-1a-targeted gene promoters. C 2 C 12 myotubes were infected with adenoviruses encoding either GFP or PGC-1a. Forty-eight hours after infection, cells were harvested and ChIP analysis using SIRT1 antibody was performed as described in Materials and methods. Values in (E) represent the mean of two experiments performed in triplicate. Error bars represent s.e.m. Statistical analyses were performed using Student's t-test. *Po0.05 and **Po0.005.
genes ( Figure 5B and Supplementary Figure S2 ). To demonstrate that these effects were dependent on SIRT1, we again used SIRT1À/À MEFs. As shown in Figure 5C , nicotinamide decreased expression of cyt-c and MCAD by approximately three-fold in SIRT1 þ / þ MEFs; however cells that lack SIRT1 did not decrease these genes in response to nicotinamide.
Moreover, and consistent with the effects of transcription on these genes, PGC-1a potently induced fatty acid oxidation that was blocked by expression of GCN5 or nicotinamide treatment ( Figure 5D ). Together, these results suggest that acetylation of PGC-1a is a regulatory chemical modification that controls the oxidative function of this transcriptional coactivator. SIRT1 is required to switch on fatty acid oxidation in response to low glucose concentrations SIRT1 and GCN5 are modulators of PGC-1a and changes of amounts and/or activities of these two enzymes will define the ability of PGC-1a to regulate metabolic genes. However, an important question is what are the stimuli or signals that are involved in this physiological process. In hepatocytes, we have shown that SIRT1 is regulated through a nutrient pathway with changes in NAD þ and pyruvate in food-deprivation conditions (Rodgers et al, 2005) . Moreover, Figure 1A shows fasting-induced PGC-1a deacetylation in skeletal muscle. In order to investigate whether SIRT1 was a target of a nutrient response in skeletal muscle cells and regulated fatty acid oxidation-a metabolic pathway that is highly induced during nutrient deprivation-we first analyzed whether changes in glucose concentration might control fatty acid oxidation rates. As shown in Figure 6A , decreases in glucose concentrations induced fatty acid oxidation up to three-fold in C 2 C 12 myotubes. Interestingly, this decrease in glucose concentration resulted in an increase of NAD þ , a substrate and activator of SIRT1, as well as an increase in the ratio of free NAD þ /NADH measured by lactate and pyruvate concentrations ( Figure 6B and Supplementary Figure S3 ). These data suggest that this change in NAD þ levels could be sensed via SIRT1 and activate its enzymatic activity. To test this, we determined acetylation levels of PGC-1a in high and low glucose concentrations. Figure 6C shows that PGC-1a acetylation is largely decreased by lowering levels of glucose, which is consistent with an increase in NAD þ and SIRT1
deacetylase activity. To demonstrate that SIRT1 mediated low glucose-induced fatty acid oxidation through regulation of gene expression, we used SIRT1À/À cells ( Figure 6D ). In SIRT1 þ / þ cells, low glucose induced expression of mitochondrial, fatty acid utilization and mitochondrial transcriptional regulator gene expression. Notably, this induction was totally blunted in SIRT1À/À MEFs. Furthermore, we tested the requirement of SIRT1 in C 2 C 12 myotubes expressing PGC1a ( Figure 6E ). As expected, low glucose induced expression of the same set of PGC-1a-targeted genes; however knockdown of SIRT1 blocked this induction. As a control, PGC-1b did not change with these treatments. Consistent with this gene expression pattern, Figure 6F shows that SIRT1À/À MEFs completely lack the ability to induce fatty acid oxidation in response to low glucose. Furthermore, knockdown of SIRT1 in C 2 C 12 myotubes also prevented the induction of fatty acid oxidation under low glucose concentrations, both in GFPand PGC-1a-expressing cells ( Figure 6F ). Taken together, these results indicate that changes in glucose concentrations that occur in physiological situations such as starvation or caloric restriction induce an autonomous switch to increase oxidation of fatty acids. Importantly, this metabolic response entirely required SIRT1 to efficiently trigger fatty acid oxidation. increases in NAD þ levels, which are sensed by the protein deacetylase SIRT1. Once activated, SIRT1 targets and deacetylates the transcriptional coactivator PGC-1a at promoter regions to induce gene expression of mitochondrial and fatty acid oxidation to maintain the bioenergetic state of the cell. This model provides a molecular mechanism by which fluctuations in nutrients target two key transcriptional regulators, SIRT1 and PGC-1a that control expression of mitochondrial oxidative genes, allowing cells to survive and adapt in periods of nutrient deprivation (Figure 7) . The ability of cells to switch from glucose to fatty acid oxidation in response to low concentrations of glucose correlates with changes in NAD þ levels. Absence or decreased levels of SIRT1 prevent this metabolic response. We propose that this is mainly due to a reduction in expression of genes involved in mitochondrial and fatty acid utilization, however the essential and required target genes are unknown. A key enzyme in this switch is PDK4, which acts by inhibition of PDH activity, thereby preventing the entry of pyruvate into the TCA cycle (Sugden et al, 1993) . In this scenario, oxidation of free fatty acids is the main supply of acetyl-CoA and NADH to the TCA and respiratory electron transport chain respectively. The fact that PDK4 is tightly controlled by SIRT1 and PGC-1a indicates that it might be a crucial target through which these transcriptional regulators control this nutrient response. In addition to PDK4 and genes of fatty acid oxidation such as CPT1b and MCAD, SIRT1 and PGC-1a also coordinate increases of genes of mitochondrial respiration. This increase is important because if the rate of fatty acid oxidation is not coupled to the use of NADH by mitochondrial respiration, it would inhibit the TCA cycle and compromise synthesis of ATP as energetic substrate for the cell. In fact, uncompleted rates of fatty acid oxidation in skeletal muscle could generate lipid intermediates that are linked to insulin resistance states (Koves et al, 2005) . In this situation, increases in NADH levels could also potentially inhibit the activity of SIRT1 as has been previously proposed (Lin et al, 2004) . Interestingly, this might suggest the existence of a negative feedback loop by increases of NADH to slow down rates of fatty acid oxidation through inhibition of SIRT1. Therefore, it is crucial in conditions of nutrient deprivation that cells maintain the ability to shift to oxidation of fatty acids and to couple it to mitochondrial respiration. Nicotinamide, an inhibitor and product of SIRT1 catalytic activity, also affected gene expression regulated by PGC-1a and prevented the low glucose response to induce oxidation of fatty acids. As nicotinamide is an endogenous inhibitor of SIRT1, it could also play a role in this metabolic response. In fact, in yeast, Pnc1p, an enzyme that synthesizes NAD þ from nicotinamide and ADP-ribose, is induced by caloric restriction, suggesting that cellular nicotinamide concentrations might modulate lifespan (Anderson et al, 2003) . In addition, in neuronal cells, caloric restriction also regulates endogenous levels of nicotinamide (Qin et al, 2006) . The levels of PGC-1a acetylation are controlled by the acetyl transferase GCN5 and SIRT1 deacetylase. It is currently not clear how or whether GCN5 is regulated or if it is constitutively active. We have shown previously that SIRT1 protein levels are increased in hepatocytes during starvation, ultimately leading to deacetylation of PGC-1a, which correlated with increases in NAD þ and pyruvate (Rodgers et al, 2005) . Interestingly, in myotubes, we did not observe any effect of pyruvate on SIRT1 protein levels (data not shown). It is conceivable that selective tissue transcription factors that interact with PGC-1a might account for these differences. However, in response to low concentrations of glucose, increased NAD þ levels correlated with PGC-1a deacetylation suggesting that SIRT1 enzymatic activity was increased. The extent to which the observed changes in NAD þ directly affect SIRT1 enzymatic activity in cells is unknown. It is possible that in addition to NAD þ , other alternative regulatory mechanisms or signaling pathways that are activated by low glucose concentrations might also regulate the activity of SIRT1 on PGC-1a. Such putative mechanisms are currently under exploration. We have previously mapped up to 13 acetylation sites on different structural domains of PGC-1a (Rodgers et al, 2005) . At this point, it is not entirely clear which acetylation residues are required for the metabolic effects. Interestingly, acetylation of PGC-1a by GCN5 drives PGC-1a to nuclear foci that are transcriptionally inactive (Lerin et al, 2006) , which could conceivably be the same mechanism that functions in myotubes. In summary, we show here that SIRT1 is an important functional regulator of PGC-1a, and that under conditions of nutrient restriction, SIRT1 regulates PGC-1a target genes and is essential in responding to increases of complete fatty acid oxidation. This is a crucial metabolic adaptation that will not only allow cells to survive periods of low nutrients, but will also integrate muscle cells in the physiological response of food deprivation to spare glucose for neuronal and red blood cells. It is also possible that this metabolic adaptation might impact the molecular mechanisms by which caloric restriction modulates lifespan. As SIRT1 is an enzyme, it encourages the possibility of screening drugs that would modulate its activity on PGC-1a and activate mitochondrial oxidative genes that are dysregulated in diseases such as diabetes and neurodegeneration.
Materials and methods
Plasmids PGC-1a, GCN5, SIRT1, control and SIRT1 shRNA adenoviruses were constructed using the pAd-Easy system as previously described (Rodgers et al, 2005) .
Animal experiments C57B1/6 mice were fed ad libitum or fasted for 16 h. Skeletal muscle whole-cell homogenates were prepared with RIPA buffer and used for Western blot analysis as previously described (Rodgers et al, 2005) .
Cell culture and adenoviral infections C 2 C 12 skeletal muscle cells were cultured in DMEM with 10% calf serum. Differentiation was induced at B90-100% confluency by switching the cell media to DMEM supplemented with 2% horse serum (HS) (differentiation media) for 72 h. Following differentiation into myotubes, C 2 C 12 cells was infected with adenovirus for 4 h in differentiation media. The media was then replaced with fresh DMEM/2%HS for an additional 48 h. The cells were then washed with PBS and incubated with indicated treatment for 12 h before collection in RIPA buffer (protein analysis) or Trizol (RNA analysis).
MEFs were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). Upon reaching 70% confluency, cells were infected for 24 h in DMEM with 10% FBS. The media was then replaced with fresh DMEM/10% FBS for an additional 48 h. The cells were washed with PBS and incubated with the indicated treatment for 12 h before collection in RIPA buffer (protein analysis) or Trizol (RNA analysis).
Primary muscle cells were isolated and cultured from 2 to 3-week-old FVB mice as described previously (Sabourin et al, 1999) . To induce differentiation, myoblasts were grown to 80% confluence and then switched to the differentiation medium, DMEM, containing 5% HS. Myotubes were transduced with adenovirus for 24 h and media were then replaced with fresh DMEM with 5% horse serum for an additional 48 h. Cells were washed with PBS and lysed in RIPA buffer. Protein lysates were subjected to Western blot analysis to determine the expression level of SIRT1 protein. Total RNA was extracted from the cells and subjected to quantitative RT-PCR analysis to determine gene expression. The Taqman primer/probe sets were purchased from ABI (assay on demand) and 18S was used for normalization. Citrate synthase activity was measured in the cells as described previously (Moyes et al, 1997) .
Gene expression analysis
Total RNA prepared from either C 2 C 12 cells or from MEFs was extracted with Trizol (Invitrogen). Complementary DNA generated by Superscript II enzyme (Invitrogen) was analyzed by quantitative reverse transcriptase-mediated PCR using an iQ SYBR Green Supermix (Bio-Rad). All data were normalized to tubulin expression. The oligonucleotide primers used are available upon request.
PGC-1a acetylation assays
PGC-1a lysine acetylation was analyzed by immunoprecipitation of PGC-1a followed by Western blot using acetyl-lysine antibodies (Cell Signalling and Technology) as previously described (Rodgers et al, 2005) . C 2 C 12 cells or MEFs were infected with adenovirus expressing Flag-tagged PGC-1a as described above. After the indicated 6 h or 12 h treatment, PGC-1a was immunoprecipitated using anti-Flag beads (Sigma) and examined for acetylation.
Fatty acid and glucose oxidation and NAD
þ measurements assays Cellular oleic and palmitic acid oxidation rates were determined in C 2 C 12 cells and MEFs using modifications of protocols previously described (Garcia-Martinez et al, 2005; Wende et al, 2005) . C 2 C 12 cells were cultured in 12-well dishes, then differentiated and infected as described above. The cells were rinsed with PBS and incubated with MEM supplemented with 0.5% HS and either 500 mM oleic or palmitic acid for 12 h. Cells were then incubated for an additional 3 h with fresh DMEM/0.5% HS that was supplemented with [1-14 C]oleic or [1-14 C]palmitic acid (3.0 mCi/mmol). The oxidation reactions were terminated and CO 2 was released from the media by the addition of 3 M perchloric acid. Filter paper saturated with phenylethylamine was placed over each well to capture CO 2 . Following a 3 h incubation with gentle shaking at 251C, 14 CO 2 resulting from oxidized fatty acid was quantified by scintillation counting of the filter paper. Each experiment was performed in triplicate and the results were normalized to total protein.
Glucose oxidation rates were measured using methods previously described (Wende et al, 2005) . NAD þ nucleotide concentration was directly measured as described (Lin et al, 2001) . In brief, a confluent 6 cm dish of C 2 C 12 myotubes was homogenized in 400 ml of acid extraction buffer to obtain the NAD þ concentration. Homogenates were neutralized with 200 ml of 0.4 M Tris buffer. The concentration of NAD þ was measured fluorometrically after an enzymatic reaction using 1.5 ml of sample. For NAD þ /NADH measurements, C 2 C 12 myotubes were deproteinized and concentrations of lactate and pyruvate were determined as previously described (Rodgers et al, 2005) .
Statistical analysis
Data are the means7s.e.m. Statistical analysis was performed by a two-tailed unpaired Student's t-test. Po0.05 was considered to be statistically significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
